Resumen de acción CLVS.Q
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 2/6 |
| Crecimiento futuro | 0/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 0/6 |
| Dividendos | 0/6 |
Competidores de Clovis Oncology, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$0.015 |
| Máximo en las últimas 52 semanas | US$2.87 |
| Mínimo de 52 semanas | US$0.01 |
| Beta | 0.66 |
| 1Cambio en 1 mes | -40.00% |
| Variación en 3 meses | -28.57% |
| Cambio de 1 año | -99.39% |
| 3Variación en 3 años | -99.77% |
| Variación en 5 años | -99.97% |
| Variación desde la OPV | -99.88% |
Noticias y actualizaciones recientes
Recent updates
Clovis Oncology rises on clinical supply agreement with Isotopia
Sep 21Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial
Sep 12Clovis Oncology: Needs Some Encouraging Data Quickly
Aug 11These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat
Aug 10
Clovis Oncology Q2 2022 Earnings Preview
Aug 05EMA recommends restricted use of Clovis cancer drug
Jul 22Clovis Oncology climbs 34% as shareholders reject reverse stock split
Jul 08Clovis: Shifting Toward Nuclear Medicine
Apr 25Clovis Oncology: Forging A Fresh Perspective
Mar 31News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat
Feb 24Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts
Jan 11Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward
Dec 30Clovis Oncology Stock: Only Glimmers Of Hope
Oct 07Clovis: Compelling With Upcoming Catalysts
Jul 30Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet
Jun 17Clovis Oncology and Inovio gain amid Reddit chatter
Jun 09Clovis Oncology: Another Upcycle Coming
May 08Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds
May 05Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)
Mar 17How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Feb 22Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan
Jan 31Clovis Oncology: Finally Green Shoots May Be On The Horizon
Jan 29Clovis Oncology reports preliminary Q4 Rubraca revenue between $43.0M to $43.5M
Jan 11What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?
Dec 31
Clovis Oncology submits FAP-2286 applications for therapeutic and imaging clinical trial
Dec 29Clovis stock rises as rubraca shows survival benefit in late-stage ovarian cancer study
Dec 21Clovis Oncology existing holder purchases additional $7.5M convertible senior notes
Nov 25Clovis Oncology: Cash Position Is Tight, We Question Management's Guidance
Nov 09Clovis Oncology: Reloading Before And After Q3 Earnings For The Long Term
Nov 06Clovis Oncology EPS beats by $0.11, misses on revenue
Nov 05Rentabilidad de los accionistas
| CLVS.Q | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 18.1% | 4.0% | 2.0% |
| 1Y | -99.4% | 18.0% | 32.4% |
Rentabilidad vs. Industria: Los resultados de CLVS.Q fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 18% el año pasado.
Rentabilidad vs. Mercado: CLVS.Q obtuvo unos resultados inferiores a los del mercado US, que fueron del 32.4% el año pasado.
Volatilidad de los precios
| CLVS.Q volatility | |
|---|---|
| CLVS.Q Average Weekly Movement | 61.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: El precio de las acciones de CLVS.Q ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de CLVS.Q ha aumentado de 39% a 61% en el último año.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2009 | 413 | Patrick Mahaffy | www.clovisoncology.com |
Resumen de fundamentos de Clovis Oncology, Inc.
| Estadísticas fundamentales de CLVS.Q | |
|---|---|
| Capitalización bursátil | US$2.18m |
| Beneficios(TTM) | -US$251.91m |
| Ingresos (TTM) | US$133.02m |
0.0x
Ratio precio-ventas (PS)0.0x
Ratio precio-beneficio (PE)¿Está CLVS.Q sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de CLVS.Q | |
|---|---|
| Ingresos | US$133.02m |
| Coste de los ingresos | US$31.59m |
| Beneficio bruto | US$101.43m |
| Otros gastos | US$353.33m |
| Beneficios | -US$251.91m |
Últimos beneficios comunicados
Sep 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.73 |
| Margen bruto | 76.25% |
| Margen de beneficio neto | -189.37% |
| Ratio deuda/patrimonio | -158.0% |
¿Cómo se ha desempeñado CLVS.Q a largo plazo?
Ver rendimiento histórico y comparativa